检索结果-南通市图书馆

多巴胺受体激动剂对帕金森病睡眠障碍影响的研究进展

在线全文

学校读者我要写书评

暂无评论

中国临床神经科学 2019年第3期27卷 335-338页

作者：王金玉潘玉君哈尔滨医科大学附属第一医院神经内科

睡眠障碍是帕金森病(PD)最常见的非运动症状之一,对患者生活质量有显著的负面影响。非麦角类多巴胺受体激动剂(如罗匹尼罗,普拉克索,罗替戈汀和阿扑吗啡,等)可以缓解PD患者的一些睡眠障碍问题,但另一些睡眠障碍问题则有可能会被诱发。虽... 详细信息

睡眠障碍是帕金森病(PD)最常见的非运动症状之一,对患者生活质量有显著的负面影响。非麦角类多巴胺受体激动剂(如罗匹尼罗,普拉克索,罗替戈汀和阿扑吗啡,等)可以缓解PD患者的一些睡眠障碍问题,但另一些睡眠障碍问题则有可能会被诱发。虽然,PD患者的睡眠障碍与普通人群中的睡眠障碍有着大多数的共同特征,然而对于PD患者群体来说,治疗睡眠障碍应有一些特殊考虑。文中就多巴胺受体激动剂改善和诱发PD患者睡眠障碍的研究进展做综述。

关键词：帕金森病多巴胺受体激动剂睡眠障碍改善诱发

变应性鼻炎防治中环境控制和健康教育的中国专家共识(2024,北京)

在线全文

学校读者我要写书评

暂无评论

中国耳鼻咽喉颅底外科杂志 2024年第4期30卷 1-11页

作者：王洪田杨钦泰叶菁余少卿许元腾孟娟杨玉成唐隽洪海裕顾瑜蓉刘文龙张维天王向东张立强许昱魏欣陈建军左可军安云芳刘锋李勇王天生陆美萍孟粹达谢志海孙悦奇邱前辉曾明许成利王英杨艳莉徐睿喻国冻石照辉叶惠平孙亚男张天虹雍军杭伟谭国林孙娜杨贵巴罗姜彦娄鸿飞叶青王学艳李华斌中国鼻病研究协作组首都医科大学附属北京世纪坛医院变态反应科北京100038 中山大学附属第三医院耳鼻咽喉头颈外科和变态反应/过敏科广东广州510630 南昌大学第一附属医院耳鼻咽喉头颈外科江西南昌330006 同济大学附属同济医院耳鼻咽喉头颈外科兼变态反应/过敏科上海200065 福建医科大学附属第一医院耳鼻咽喉科/过敏中心福建福州350004 四川大学华西医院耳鼻咽喉头颈外科四川成都610041 重庆医科大学附属第一医院耳鼻咽喉头颈外科重庆400016 佛山市第一人民医院耳鼻咽喉头颈外科广东佛山528000 中山大学附属第五医院耳鼻咽喉头颈外科/过敏反应中心广东珠海519000 复旦大学附属眼耳鼻喉科医院耳鼻咽喉科上海200031 广州医科大学附属妇女儿童医疗中心耳鼻咽喉头颈外科广东广州510623 上海交通大学医学院附属第六人民医院耳鼻咽喉头颈外科上海200233 首都医科大学附属北京同仁医院耳鼻咽喉头颈外科北京100730 山东大学齐鲁医院耳鼻咽喉科山东济南250012 武汉大学人民医院耳鼻咽喉头颈外科湖北武汉430060 海南省人民医院/海南医学院附属海南医院耳鼻咽喉头颈外科海南海口570311 华中科技大学同济医学院附属协和医院耳鼻咽喉科湖北武汉430022 中山大学附属第一医院耳鼻咽喉科医院耳鼻咽喉科广东广州510080 山西医科大学第二医院耳鼻咽喉科山西太原030001 浙江大学医学院附属杭州市第一人民医院耳鼻咽喉头颈外科浙江杭州310016 中南大学湘雅三医院耳鼻咽喉头颈外科湖南长沙410013 南京医科大学第一附属医院耳鼻咽喉科江苏南京210029 吉林大学中日联谊医院耳鼻咽喉头颈外科吉林长春130033 中南大学湘雅医院耳鼻咽喉头颈外科湖南长沙410008 中山大学附属第七医院耳鼻咽喉科广东深圳518107 广东省人民医院耳鼻咽喉头颈外科广东广州510080 华中科技大学同济医学院附属同济医院耳鼻咽喉头颈外科湖北武汉430030 广西医科大学第二附属医院耳鼻咽喉头颈外科广西南宁530007 郑州大学第一附属医院鼻科河南郑州450052 昆明医科大学第一附属医院耳鼻咽喉科云南昆明650032 贵州医科大学附属医院耳鼻咽喉头颈外科贵州贵阳550004 贵州省人民医院耳鼻咽喉科贵州贵阳550002 哈尔滨医科大学附属第一医院耳鼻咽喉头颈外科黑龙江哈尔滨150001 哈尔滨医科大学附属第二医院耳鼻咽喉头颈外科黑龙江哈尔滨150001 新疆医科大学第一附属医院耳鼻咽喉科新疆乌鲁木齐830054 天津市环湖医院耳鼻咽喉头颈外科天津300350 上海中医药大学附属光华医院耳鼻咽喉头颈外科上海200052 深圳市龙岗中心医院耳鼻咽喉科/变态反应科广东深圳518116 西藏自治区人民医院耳鼻咽喉科西藏拉萨850000 青岛大学附属医院耳鼻咽喉头颈外科山东青岛266003 福建医科大学省立临床医学院福建省立医院耳鼻咽喉头颈外科福建福州350001 首都医科大学附属北京世纪坛医院变态反应中心北京100038 不详

尽管国内外变应性鼻炎(AR)诊疗指南均一致认可“防治结合、四位一体”的治疗策略,但是相对于过敏原检测、抗过敏药物治疗、过敏原免疫治疗(AIT)而言,人们对环境控制和健康教育的重视程度不够、研究较少、文献数量也不多。有鉴于此,中国... 详细信息

尽管国内外变应性鼻炎(AR)诊疗指南均一致认可“防治结合、四位一体”的治疗策略,但是相对于过敏原检测、抗过敏药物治疗、过敏原免疫治疗(AIT)而言,人们对环境控制和健康教育的重视程度不够、研究较少、文献数量也不多。有鉴于此,中国鼻病研究协作组的中青年专家们集体撰写了本共识,以期为临床医生进行环境控制和健康教育提供指导和帮助,提高AR防治效果。

关键词：变应性鼻炎过敏原免疫治疗环境控制健康教育预防

维普期刊数据库博看期刊

中国多巴胺能PET联合葡萄糖代谢PET脑显像在帕金森病临床应用专家共识

在线全文

学校读者我要写书评

暂无评论

中国临床神经科学 2024年第4期32卷 361-372页

作者：左传涛刘丰韬田梅管一晖张宏鲁佳荧李欣忆琚紫昭葛璟洁吴平张军罗巍豆晓锋于聪聪钟燕金晨涛周瑞侯海峰占宏伟卢洁王瑞民李彪尹雅芙李雪娜朱小华朱元凯兰晓莉姜磊何勇田蓉范岩孙夕林赵军富丽萍蒋韩马晓芬张丽霞丁正同王坚中国认知科学学会分子影像分会复旦大学附属华山医院核医学/PET中心上海200235 复旦大学附属华山医院神经内科上海200040 浙江大学医学院附属第二医院核医学科/PET中心杭州310009 复旦大学附属华山医院放射科上海200040 浙江大学医学院附属第二医院神经内科杭州310009 首都医科大学宣武医院放射与核医学科北京100053 中国人民解放军总医院第一医学中心核医学科北京100853 上海交通大学医学院附属瑞金医院核医学科上海200025 上海交通大学医学院附属新华医院核医学科上海200092 中国医科大学附属第一医院核医学科沈阳110001 华中科技大学同济医学院附属同济医院核医学科武汉430030 华中科技大学同济医学院附属协和医院核医学科武汉430022 广东省人民医院核医学科广州510080 武汉大学中南医院核医学科武汉430071 四川大学华西医院核医学科成都610041 北京大学第一医院核医学科北京100034 哈尔滨医科大学附属第四医院核医学科哈尔滨150001 同济大学附属东方医院核医学科上海200120 中日友好医院核医学科北京100029 福建医科大学附属协和医院PET/CT室福州350001 广东省第二人民医院核医学科广州510317 浙江省中医院核医学科杭州310006 中国认知科学学会分子影像分会杭州310009

多巴胺能正电子发射断层扫描(PET)脑显像是目前诊断帕金森病的重要依据,但其对帕金森综合征的鉴别能力有限。葡萄糖代谢PET显像中不同的脑代谢模式为进一步鉴别诊断提供可能。文中在前期PET脑显像相关技术操作和临床应用专家共识的基础... 详细信息

多巴胺能正电子发射断层扫描(PET)脑显像是目前诊断帕金森病的重要依据,但其对帕金森综合征的鉴别能力有限。葡萄糖代谢PET显像中不同的脑代谢模式为进一步鉴别诊断提供可能。文中在前期PET脑显像相关技术操作和临床应用专家共识的基础上,对开展多巴胺能联合葡萄糖代谢显像进行系统梳理,征求专家意见后形成本专家共识。旨在规范帕金森综合征患者的多巴胺能显像及葡萄糖代谢显像的技术操作,为医生提供报告解读建议,进一步指导多巴胺能与葡萄糖代谢PET脑显像联合应用在帕金森相关疾病中的临床实践流程。

关键词：帕金森综合征帕金森病正电子发射断层扫描多巴胺能显像葡萄糖代谢显像联合应用

白三烯受体拮抗剂在儿童变应性鼻炎中的临床应用专家共识(2023,广州)

在线全文

学校读者我要写书评

暂无评论

中国眼耳鼻喉科杂志 2024年第3期24卷 161-169页

作者：刘文龙罗茜曾清香杨钦泰邱前辉徐睿孙悦奇杨贵唐隽洪海裕许元腾石照辉魏欣王天生孟娟杨玉成王英娄鸿飞孟粹达叶菁张立强杨艳莉安云芳陆美萍曾明王向东陈建军雍军余少卿张维天孙亚男张天虹孙娜李幼瑾刘翔李健左可军罗向前王洪田许昱喻国冻付勇叶惠平李勇许成利李华斌中国鼻病研究协作组广州医科大学附属妇女儿童医疗中心耳鼻咽喉科广州510623 中山大学附属第三医院耳鼻咽喉头颈外科和变态反应(过敏)科广州510630 广东省人民医院耳鼻咽喉头颈外科广州510080 中山大学附属第一医院耳鼻咽喉科医院变态反应专科广州510080 中山大学附属第七医院耳鼻咽喉科深圳518107 深圳市龙岗中心医院耳鼻咽喉科深圳518116 佛山市第一人民医院耳鼻咽喉头颈外科佛山520800 中山大学附属第五医院耳鼻咽喉科珠海519000 福建医科大学附属第一医院耳鼻咽喉头颈外科福州350004 海南省人民医院海南医学院附属海南医院耳鼻咽喉头颈外科海口570311 中南大学湘雅三医院耳鼻咽喉头颈外科长沙410013 四川大学华西医院耳鼻咽喉头颈外科成都610041 重庆医科大学附属第一医院耳鼻咽喉头颈外科重庆400016 郑州大学第一附属医院鼻科郑州450052 复旦大学附属眼耳鼻喉科医院耳鼻喉科上海200031 吉林大学中日联谊医院耳鼻咽喉头颈外科长春130033 南昌大学第一附属医院耳鼻咽喉头颈外科南昌330006 山东大学齐鲁医院耳鼻咽喉科济南250012 昆明医科大学第一附属医院耳鼻喉一科昆明650032 山西医科大学第二医院耳鼻咽喉科太原030001 南京医科大学第一附属医院耳鼻咽喉科南京210029 华中科技大学同济医学院附属同济医院耳鼻咽喉头颈外科武汉430030 首都医科大学附属北京同仁医院耳鼻咽喉头颈外科北京100730 华中科技大学同济医学院附属协和医院耳鼻咽喉科武汉430022 新疆医科大学第一附属医院耳鼻咽喉科乌鲁木齐830054 同济大学附属同济医院耳鼻咽喉头颈外科上海200065 上海交通大学附属第六人民医院耳鼻咽喉头颈外科上海200233 哈尔滨医科大学附属第二医院耳鼻咽喉头颈外科哈尔滨150001 哈尔滨医科大学附属第一医院耳鼻咽喉头颈外科哈尔滨150007 上海中医药大学附属光华中西医结合医院耳鼻咽喉头颈外科上海200040 上海交通大学医学院附属上海儿童医学中心耳鼻喉口腔颌面外科上海200127 中山大学孙逸仙纪念医院耳鼻咽喉科广州510120 中山大学附属第一医院耳鼻咽喉科医院耳鼻咽喉头颈外科广州510080 南方医科大学深圳医院儿童耳鼻咽喉科深圳518101 首都医科大学附属北京世纪坛医院变态反应科北京100038 武汉大学人民医院耳鼻咽喉头颈外科武汉430060 贵州医科大学附属医院耳鼻咽喉头颈外科贵阳550004 浙江大学医学院附属儿童医院耳鼻咽喉头颈外科杭州310005 贵州省人民医院耳鼻咽喉科贵阳550499 浙江大学医学院附属杭州市第一人民医院耳鼻咽喉科杭州310003 广西医科大学第二附属医院耳鼻咽喉头颈外科南宁530005 不详

半胱氨酸白三烯(CysLT)是免疫细胞合成和分泌的炎性介质,与细胞膜上的受体结合发挥生物学效应,参与多种过敏性疾病的发病。抗白三烯药物有两类:CysLT1受体拮抗剂(LTRA)和白三烯合成抑制剂,前者与CysLT1受体结合,从而干扰过敏性炎症的发... 详细信息

半胱氨酸白三烯(CysLT)是免疫细胞合成和分泌的炎性介质,与细胞膜上的受体结合发挥生物学效应,参与多种过敏性疾病的发病。抗白三烯药物有两类:CysLT1受体拮抗剂(LTRA)和白三烯合成抑制剂,前者与CysLT1受体结合,从而干扰过敏性炎症的发生。LTRA在儿童过敏性疾病的治疗中广泛应用,但仍存在质疑与挑战。因此,中国鼻病研究协作组召集国内中青年鼻科专家,制订了LTRA治疗儿童变应性鼻炎专家共识,旨在指导儿童变应性鼻炎临床诊疗工作。目前国内外指南均推荐LTRA作为儿童变应性鼻炎治疗的一线药物。儿童对孟鲁司特一般耐受性良好,总体不良反应发生率与安慰剂相似,对神经精神影响的研究尚无统一意见,临床医师应意识到神经精神事件的潜在风险,在开具相应处方时注意权衡利弊。

关键词：白三烯受体拮抗剂儿童变应性鼻炎

在线全文

学校读者我要写书评

暂无评论

136例巨大结节性甲状腺肿手术结果分析

中国地方病学杂志 2007年第4期26卷 453-454页

作者：王毓利王凤军周保国乔海泉哈尔滨医科大学第一临床医学院普外科 150001

目的分析巨大结节性甲状腺肿手术结果，探讨手术并发症的预防和治疗。方法采用回顾性分析方法．收集1991—2006年间在哈尔滨医科大学第一临床医学院普外科采用甲状腺大部切除术或甲状腺次全切除术的巨大结节性甲状腺肿患者的临床资料... 详细信息

目的分析巨大结节性甲状腺肿手术结果，探讨手术并发症的预防和治疗。方法采用回顾性分析方法．收集1991—2006年间在哈尔滨医科大学第一临床医学院普外科采用甲状腺大部切除术或甲状腺次全切除术的巨大结节性甲状腺肿患者的临床资料，分析手术并发症产生的原因。结果巨大结节性甲状腺肿患者136例．术后发生喉返神经损伤5例（3．7％），切口内出血2例（1．5％），甲状旁腺损伤3例（2-2％），喉上神经损伤1例（0．7％）。结论术前充分准备，选择合适麻醉方式，运用综合无血手术野操作，能够预防巨大结节性甲状腺肿手术并发症的发生。

关键词：甲状腺,结节性甲状腺切除术并发症

The Chinese Society of clinical Oncology(CSCO):clinical guidelines for the diagnosis and treatment of gastric cancer,2021

在线全文

学校读者我要写书评

暂无评论

Cancer Communications 2021年第8期41卷 747-795页

作者： Feng-Hua Wang Xiao-Tian Zhang Yuan-Fang Li Lei Tang Xiu-Juan Qu Jie-Er Ying jun Zhang Ling-Yu Sun Rong-Bo Lin Hong Qiu Chang Wang Miao-Zhen Qiu Mu-Yan Cai QiWu Hao Liu Wen-Long Guan Ai-Ping Zhou Yu-Jing Zhang Tian-Shu Liu Feng Bi Xiang-Lin Yuan Sheng-Xiang Rao Yan Xin Wei-Qi Sheng Hui-Mian Xu Guo-Xin Li Jia-Fu Ji Zhi-Wei Zhou Han Liang Yan-Qiao Zhang Jing Jin Lin Shen Jin Li Rui-Hua Xu department of medical Oncology State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China department of Gastrointestinal Oncology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142P.R.China department of Gastric surgery State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center for Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China department of Radiology Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142P.R.China department of medical Oncology The First Hospital of China Medical UniversityShenyangLiaoning 110001P.R.China department of medical Oncology Zhejiang Cancer HospitalHangzhouZhejiang 310006P.R.China department of medical Oncology Ruijin HospitalShanghai Jiaotong University School of MedicineShanghai 200025P.R.China department of Surgical Oncology The Fourth Affiliated Hospital of Harbin Medical UniversityHarbinHeilongjiang 150001P.R.China department of medical Oncology Fujian Cancer HospitalFuzhouFujian 350000P.R.China department of medical Oncology Tongji Hospital Affiliated to Tongji Medical College of Huazhong University of Science and TechnologyWuhanHubei 430030P.R.China Cancer Center of The first hospital of Jilin university ChangchunJilin 130021P.R.China department of Pathology State Key Laboratory of Oncology in South ChinaCollaborative Innovation Center of Cancer MedicineSun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China department of Endoscopy Center Key Laboratory of Carcinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital and InstituteBeijing 100142P.R.China department of general surgery Nanfang HospitalSouthern Medical UniversityGuangzhouGuan

There exist differences in the epidemiological characteristics,clinicopathological features,tumor biological characteristics,treatment patterns,and drug selections between gastric cancer patients from the Eastern and Western *** Chinese Society of clinical Oncology(CSCO)has organized a panel of senior experts specializing in all sub-specialties of gastric cancer to compile a clinical guideline for the diagnosis and treatment of gastric cancer since 2016 and renews it *** into account regional differences,giving full consideration to the accessibility of diagnosis and treatment resources,these experts have conducted expert consensus judgment on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes in *** 2021 CSCO clinical Practice Guidelines for Gastric Cancer covers the diagnosis,treatment,follow-up,and screening of gastric *** on the 2020 version of the CSCO Chinese Gastric Cancer guidelines,this updated guideline integrates the results ofmajor clinical studies from china and overseas for the past year,focused on the inclusion of research data from the Chinese population for more personalized and clinically relevant *** the comprehensive treatment of non-metastatic gastric cancer,attentions were paid to neoadjuvant *** value of perioperative chemotherapy is gradually becoming clearer and its recommendation level has been *** the comprehensive treatment of metastatic gastric cancer,recommendations for immunotherapy were included,and immune checkpoint inhibitors fromthird-line to the first-line of treatment for different patient groups with detailed notes are provided.

关键词： adjuvant chemotherapy Chinese Society of clinical Oncology(CSCO) diagnosis gastric cancer immunotherapy neoadjuvant radiotherapy surgery targeted therapy

Prevalence of Nontraumatic Osteonecrosis of the Femoral Head and its Associated Risk Factors in the Chinese Population： Results from a Nationally Representative Survey

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Chinese medical Journal 2015年第21期128卷 2843-2850页

作者： De-Wei Zhao Mang Yu Kai Hu Wei Wang Lei Yang Ben-Jie Wang Xiao-Hong Gao Yong-Ming Guo Yong-Qing Xu Yu-Shan Wei Si-Miao Tian Fan Yang Nan Wang Shi-Bo Huang Hui Xie Xiao-Wei Wei Hai-Shen Jiang Yu-Qiang Zang jun Ai Yuan-Liang Chen Guang-Hua Lei Yu-Jin Li Geng Tia Zong-Sheng Li Yong Cao Li Ma Orthopedic medical Research Center Dalian University Dalian Liaoning 116001 China department of Orthopaedics Affiliated Zhongshan Hospital of Dalian University Dalian Liaoning 116001 China department of Pathology Stanford University School of Medicine Stanford CA USA medical Clinic I University Hospital Wurzburg Worzburg Germany department of Epidemiology and Statistics School of Public Health Dalian Medical University Oalian Liaoning 116044 China department of Orthopaedics Xi'an 521 Hospital Xi'an Shaanxi 710065 China department of Orthopaedics Kunming General Hospital of Chengdu Military Region Kunming Yunnan 650032 China department of clinical Laboratory Affiliated Zhongshan Hospital of Dalian University Dalian Liaoning 116001 China department of Orthopaedics The First People's Hospital of Horqin District Tongliao Inner Mongolia 028000 China department of Orthopaedics The People's Hospital of Changhai County Dalian Liaoning 116500 China department of Health Kunming Kun Lu Hospital Kunming Yunnan 650217 China department of Orthopaedics The People's Hospital of Haikou Haikou Hainan 570208 China department of Orthopaedics Xiangya Hospital of Central South University Changsha Hunan 410008 China department of Orthopaedics The People's Hospital of Fangzheng County Harbin Heilongjiang 150800 China department of Orthopaedics The People's Hospital of Qionghai Qionghai Hainan 571400 China department of Imaging Traditional Chinese Medicine Orthopedics Hospital of Xiaoshan Hangzhou Zhejiang 311261 China department of Imaging Red Star Hospital of Agricultural Thirteen Division of Hami Hami Xinjiang 839000 China

Background： Nontraumatic osteonecrosis of the femoral head （NONFH） is a debilitating disease that represents a significant financial burden for both individuals and healthcare systems. Despite its significance, however, its prevalence in the Chinese general population remains unknown. This study aimed to investigate the prevalence of NONFH and its associated risk factors in the Chinese population. Methods： A nationally representative survey of 30,030 respondents was undertaken from june 2012 to August 2013. All participants underwent a questionnaire investigation, physical examination of hip, and bilateral hip joint X-ray and/or magnetic resonance imaging exalnination. Blood samples were taken after overnight fasting to test serum total cholesterol, triglyceride, and high-density lipoprotein （HDL） and low-density lipoprotein （LDL） levels. We then used multivariate logistic regression analysis to investigate the associations between various metabolic, demographic, and lifestyle-related variables and NONFH. Results： NONFH was diagnosed in 218 subjects （0.725%） and the estimated NONFH cases were 8.12 million among Chinesepeople aged 15 years and over. The prevalence of NONFH was significantly higher in males than in females （1.02% vs. 0.51%, x^2 = 24.997, P 〈 0.001 ）. Among NONFH patients, North residents were subjected to higher prevalence of NONFH than that of South residents （0.85% vs. 0.61%,x^2= 5.847, P = 0.016）. Our multivariate regression analysis showed that high blood levels oftriglycerides, total cholesterol, LDL-cholesterol, and non-H DL-cholesterol, male, urban residence, family history of osteonecrosis of the femoral head. heavy smoking, alcohol abuse and glucocorticoid intake, overweight, and obesity were all significantly associated with an increased risk of NONFH. Conclusions： Our findings highlight that NONFH is a significantpublic health challenge in china and underscore the need for policy measures on the national level. Furthermore, NONFH shares a n

关键词： Nontraumatic Osteonecrosis of the Femoral Head Prevalence Risk Factors

Bendamustine treatment of Chinese patients with relapsed indolent non-Hodgkin lymphoma: a multicenter, open-label, single-arm, phase 3 study

在线全文

学校读者我要写书评

暂无评论

Chinese medical Journal 2021年第11期134卷 1299-1309页

作者： Yuan-Kai Shi Xiao-Nan Hong Jian-Liang Yang Wei Xu Hui-Qiang Huang Xiu-Bin Xiao jun Zhu Dao-Bin Zhou Xiao-Hong Han Jian-Qiu Wu Ming-Zhi Zhang Jie Jin Xiao-Yan Ke Wei Li De-Pei Wu Shen-Miao Yang Xin Du Yong-Qian Jia Ai-Chun Liu Dai-Hong Liu Zhi-Xiang Shen Lian-Sheng Zhang Leonard James Edward Hellriegel department of medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted DrugsBeijing 100021China department of medical Oncology Fudan University Shanghai Cancer CenterShanghai 200030China department of Hematology The First Affiliated Hospital of Nanjing Medical UniversityNanjingJiangsu 210029China department of medical Oncology Sun Yat-sen University Cancer CenterGuangzhouGuangdong 510060China department of medical Oncology 307 Hospital of Chinese People’s Liberation ArmyBeijing 100071China department of Lymphoma Peking University Cancer Hospital&InstituteBeijing 100142China department of Hematology Peking Union Medical College HospitalChinese Academy of Medical Sciences&Peking Union Medical CollegeBeijing 100730China department of Oncology Jiangsu Cancer Hospital&Jiangsu Institute of CancerNanjingJiangsu 210009China department of Oncology The First Affiliated Hospital of Zhengzhou UniversityZhengzhouHenan 450052China department of Hematology The First Affiliated Hospital of Zhejiang University College of MedicineHangzhouZhejiang 310003China department of Hematology Peking University Third HospitalBeijing 100191China department of Oncology Jilin University First Affiliated HospitalChangchunJilin 130021China department of Hematology Jiangsu Institute of HematologyThe First Affiliated Hospital of Soochow UniversitySuzhouJiangsu 215006China department of Hematology Peking University Institute of HematologyPeking University People’s HospitalBeijing 100044China department of Hematology Guangdong General HospitalGuangzhouGuangdong 510062China department of Hematology and Research Laboratory of Hematology West China Hospital of Sichuan UniversityChengduSichuan 610041China department of medical Oncology Harbin Medical University Cancer HospitalHarbinHeilongjiang 150001China department of Hematolo

Background:Bendamustine was approved in china on May 26th,2019 by the National medical Product Administration for the treatment of indolent B-cell non-Hodgkin lymphoma(NHL).The current study was the registration trial and the first reported evaluation of the efficacy,safety,and pharmacokinetics of bendamustine in Chinese adult patients with indolent B-cell NHL following relapse after chemotherapy and rituximab ***:This was a prospective,multicenter,open-label,single-arm,phase 3 study(NCT01596621;C18083/3076)with a 2-year follow-up *** patients received bendamustine hydrochloride 120 mg/m2 infused intravenously on days 1 and 2 of each 21-day treatment cycle for at least six planned cycles(and up to eight cycles).The primary endpoint was the overall response rate(ORR);and secondary endpoints were duration of response(DoR),progression-free survival(PFS),safety,and *** were classified according to their best overall response after initiation of *** of patients in each response category(complete response[CR],partial response[PR],stable disease,or progressive disease)were summarized along with a twosided binomial exact 95%confidence intervals(CIs)for the ***:A total of 102 patients were enrolled from 20 centers between August 6th,2012,and june 18th,*** the time of the primary analysis,the ORR was 73%(95%CI:63%–81%)per Independent Review Committee(IRC)including 19%CR and 54%*** the follow-up period,the median DoR was 16.2 months by IRC and 13.4 months by investigator assessment;the median PFS was 18.6 months and 15.3 months,*** most common non-hematologic adverse events(AEs)were gastrointestinal toxicity,pyrexia,and *** 3/4 neutropenia was reported in 76%of *** AEs were reported in 29 patients and five patients died during the *** analysis indicated that the characteristics of bendamustine and its metabolites M3 and M4 were generally consistent

关键词： Bendamustine Non-Hodgkin lymphoma B-cell malignancy Relapsed disease clinical trial

Application of next-generation sequencing technology to precision medicine in cancer: joint consensus of the Tumor Biomarker Committee of the Chinese Society of clinical Oncology

在线全文

学校读者我要写书评

暂无评论

Cancer Biology & Medicine 2019年第1期16卷 189-204页

作者： Xuchao Zhang Zhiyong Liang Shengyue Wang Shun Lu Yong Song Ying Cheng Jianming Ying Weiping Liu Yingyong Hou Yangqiu Li Yi Liu jun Hou Xiufeng Liu Jianyong Shao Yanhong Tai Zheng Wang Li Fu Hui Li Xiaojun Zhou Hua Bai Mengzhao Wang You Lu Jinji Yang Wenzhao Zhong Qing Zhou Xuening Yang Jie Wang Cheng Huang Xiaoqing Liu Xiaoyan Zhou Shirong Zhang Hongxia Tian Yu Chen Ruibao Ren Ning Liao Chunyan Wu Zhongzheng Zhu Hongming Pan Yanhong Gu Liwei Wang Yunpeng Liu Suzhan Zhang Tianshu Liu Gong Chen Zhimin Shao Binghe Xu Qingyuan Zhang Ruihua Xu Lin Shen Yilong Wu Guangdong Lung Cancer Institute Medical Research Center Cancer Center of Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences Affiliated Guangdong Provincial People's hospital South China University of Technology department of Pathology Peking Union Medical College Hospital Chinese Academy of Medical Sciences National Research Center for Translational Medicine Shanghai Rui Jin Hospital Shanghai Jiao Tong University School of Medicine Lung Tumor clinical medical Center Shanghai Chest Hospital Shanghai Jiao Tong University Division of Respiratory Medicine Jinling Hospital Nanjing University School of Medicine department of Oncology Jilin Cancer Hospital department of Pathology National Cancer Center/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College department of Pathology West China Hospital Sichuan University department of Pathology Zhongshan Hospital Fudan University department of Hematology First Affiliated Hospital Institute of Hematology School of Medicine Jinan University Laboratory of Oncology Affiliated Hospital of the Academy of Military Medical Sciences department of Oncology First Clinical College of South China University of Technology/Guangdong Lung Cancer Institute People's Liberation Army Cancer Center of Bayi hospital Affiliated to Nanjing university of Chinese Medicine department of Pathology Sun Yat-sen University Cancer Center department of Pathology Affiliated Hospital of the Academy of Military Medical Sciences department of Pathology Beijing Hospital department of Breast Cancer Pathology and Research Laboratory of Cancer Tianjin Medical University Cancer Institute and Hospital National Clinical Research Center for Cancer Key Laboratory of Cancer Prevention and Therapy Tianjin Tianjin’s Clinical Research Center for Cancer department of Pathology Jinling Hospital Nanjing University School of Medicine State Key Laboratory of Molecular Oncology Department of Medical Oncology National Cancer Center/Canc

Next-generation sequencing(NGS) technology is capable of sequencing millions or billions of DNA molecules ***, it represents a promising tool for the analysis of molecular targets for the initial diagnosis of disease, monitoring of disease progression, and identifying the mechanism of drug resistance. On behalf of the Tumor Biomarker Committee of the Chinese Society of clinical Oncology(CSCO) and the china Actionable Genome Consortium(CAGC), the present expert group hereby proposes advisory guidelines on clinical applications of NGS technology for the analysis of cancer driver genes for precision cancer therapy. This group comprises an assembly of laboratory cancer geneticists, clinical oncologists, bioinformaticians,pathologists, and other professionals. After multiple rounds of discussions and revisions, the expert group has reached a preliminary consensus on the need of NGS in clinical diagnosis, its regulation, and compliance standards in clinical sample collection. Moreover, it has prepared NGS criteria, the sequencing standard operation procedure(SOP), data analysis, report, and NGS platform certification and validation.

关键词： Next-generation sequencing technology cancer consensus